Laquinimod sodium is an orally available carboxamide derivative that acts as a potent immunomodulator, preventing neurodegeneration and inflammation in the central nervous system; it reduces astrocytic NF-κB activation to prevent cuprizone-induced demyelination; it has potential applications in the treatment of relapsing-remitting (RRMS) and chronic progressive (CPMS) forms of multiple sclerosis (MS) as well as in research on neurodegenerative diseases.